Evidence map›Paper›PMID 42848862›Full record

ArticleCirculation research2026

Big Job for the Small Titin: Don't Underestimate the "Little" Guy.

Michaela M Door, Jonathan A Kirk

Abstract readEditorial
In one paragraph

Article in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michaela M DoorCenter for Cardiovascular Research, Department of Medicine, University of Chicago, Chicago, IL (M.M.D., J.A.K.).ORCID 0009-0009-3131-2887
Jonathan A KirkCenter for Cardiovascular Research, Department of Medicine, University of Chicago, Chicago, IL (M.M.D., J.A.K.).ORCID 0000-0002-5192-2860

Funding

GSK-3β Localizes to the Myofilament and Modifies its Function in Ischemic CardiomyopathyR01HL136737 · NHLBI · UNIVERSITY OF CHICAGO · PI JONATHAN A KIRK · 2017 to 2026
$4.5M
Broadly applicable high throughput variant interpretation and validation for MYH7R01HL175964 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI JONATHAN A KIRK, Md. Abul Hassan Samee · 2024 to 2026
$2.1M
Structural and functional basis of myocardial dysregulation in genetic cardiomyopathyR01HL172492 · NHLBI · UNIVERSITY OF CHICAGO · PI THOMAS C IRVING, JONATHAN A KIRK · 2024 to 2026
$2.1M
AAV-mediated PERM1 Overexpression as a New Therapy for Heart Failure with Reduced Ejection FractionR01HL184522 · NHLBI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Kiyotake Ishikawa, JONATHAN A KIRK · 2026 to 2026
$1.6M
NHLBI NIH HHS R01 HL136737NHLBI NIH HHS R01 HL172492NHLBI NIH HHS R01 HL175964NHLBI NIH HHS R01 HL184522
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiomyopathiesconnectinEditorialsglycogen synthase kinasessarcomeres

Identifiers

PMID42848862
PMCPMC13651585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.